GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Total Assets

Infant Bacterial Therapeutics AB (OSTO:IBT B) Total Assets : kr207.92 Mil (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Total Assets?

Infant Bacterial Therapeutics AB's Total Assets for the quarter that ended in Mar. 2025 was kr207.92 Mil.

During the past 12 months, Infant Bacterial Therapeutics AB's average Total Assets Growth Rate was -58.80% per year. During the past 3 years, the average Total Assets Growth Rate was -9.40% per year. During the past 5 years, the average Total Assets Growth Rate was -7.70% per year. During the past 10 years, the average Total Assets Growth Rate was -0.90% per year.

During the past 11 years, Infant Bacterial Therapeutics AB's highest 3-Year average Total Assets Growth Rate was 17.10%. The lowest was -17.80%. And the median was -2.65%.

Total Assets is connected with ROA %. Infant Bacterial Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2025 was -29.93%. Total Assets is also linked to Revenue through Asset Turnover. Infant Bacterial Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2025 was 0.00.


Infant Bacterial Therapeutics AB Total Assets Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Total Assets Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 450.32 408.48 349.62 351.33 239.57

Infant Bacterial Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 348.88 296.44 239.30 239.57 207.92

Infant Bacterial Therapeutics AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Infant Bacterial Therapeutics AB's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=170.263+69.303
=239.57

Infant Bacterial Therapeutics AB's Total Assets for the quarter that ended in Mar. 2025 is calculated as

Total Assets=Total Equity (Q: Mar. 2025 )+Total Liabilities (Q: Mar. 2025 )
=153.524+54.392
=207.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infant Bacterial Therapeutics AB  (OSTO:IBT B) Total Assets Explanation

Total Assets is connected with ROA %.

Infant Bacterial Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2025 is

ROA %=Net Income (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=-66.956/( (239.566+207.916)/ 2 )
=-66.956/223.741
=-29.93 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Infant Bacterial Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2025 is

Asset Turnover
=Revenue (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=0/( (239.566+207.916)/ 2 )
=0/223.741
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Infant Bacterial Therapeutics AB Total Assets Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines